Griseofulvin
- Generic Name
- Griseofulvin
- Brand Names
- Gris-peg
- Drug Type
- Small Molecule
- Chemical Formula
- C17H17ClO6
- CAS Number
- 126-07-8
- Unique Ingredient Identifier
- 32HRV3E3D5
- Background
An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections.
- Indication
For the treatment of ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap or other conditions caused by Trichophyton or Microsporum fungi.
- Associated Conditions
- Tinea Capitis, Tinea Corporis, Tinea Cruris, Tinea Pedis, Tinea Unguium, Tinea barbae
- Associated Therapies
- -
Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 70
- Registration Number
- NCT01518166
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Uppsala, Sweden
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 720
- Registration Number
- NCT00117767
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath